U.S. stock market quick update: Alaunos Therapeutics up 8.92%

U.S. Stock Market Midday Update Stocks with High Trading Volume in the Industry Akero Therapeutics rose 16.43%. According to recent important news: On October 9, Novo Nordisk announced the acquisition of Akero Therapeutics for up to $5.2 billion, driving its stock price up 16.5%. The deal includes $54 per share in cash and $6 in contingent value rights, a premium of 16.2% over the previous day's closing price. Source: Reuters. On October 9, Akero's drug efruxifermin is in Phase III clinical trials, expected to complement Novo Nordisk's leading position in metabolic therapies. This news further boosted the stock price. Source: Caixin. On October 9, the MASH therapeutic market became a hotspot for mergers and acquisitions, and Akero's drug aligns with Novo Nordisk's product portfolio, expected to launch in 2028. Against this backdrop, the acquisition news had a positive impact on the stock price. Source: Bloomberg Industry Research. The MASH market is active in M&A, and risks should be monitored. AbbVie fell 0.02%, with a trading volume of $531 million. According to recent key news: On October 8, AbbVie submitted a new drug application and announced an expansion of its bioresearch center in Massachusetts, investing $70 million. This news boosted market confidence in the company's future growth but did not significantly drive up the stock price. On October 7, Carolina Wealth Advisors disclosed in a filing with the U.S. Securities and Exchange Commission that it had sold 38,267 shares of AbbVie stock, with a transaction amount of approximately $7.79 million. This large-scale sell-off raised short-term pressure on the company's stock. On October 7, AbbVie won a tax dispute with the IRS, and the tax court's ruling was favorable for the company, but the market reaction was muted. The pharmaceutical industry is performing steadily overall, with active capital flows